arrow
C

Collin M. Blakely

University of California San Francisco
H指数:38
被引数:8,549

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Targeting WEE1 to Overcome ARID1A Mutation-Driven Osimertinib Resistance in EGFR-Mutant Lung Cancer

靶向WEE1以克服ARID1A突变驱动的奥希替尼耐药性在EGFR突变型肺癌中

2025-06-130
OAAI
Sitravatinib in patients with solid tumors selected by molecular alterations: results from a Phase Ib study

通过分子改变选择的实体瘤患者的sitratinib: Ib期研究的结果

2024-11-080
OAAI
CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors

CTLA4阻断消除KEAP1/STK11-related对PD-(L)1抑制剂的抗性

Nature
IF48.5
2024-10-090
OAAI
Focal adhesion kinase-YAP signaling axis drives drug-tolerant persister cells and residual disease in lung cancer
2024-05-0310
OAAI
PERCEPTION predicts patient response and resistance to treatment using single-cell transcriptomics of their tumors

PERCEPTION使用肿瘤的单细胞转录组学预测患者对治疗的反应和抵抗力

2024-04-188
OA
The role of APOBEC3B in lung tumor evolution and targeted cancer therapy resistance
2023-12-0419
OAAI
Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC

KRASG12C抑制剂在晚期NSCLC中的疗效和作用

2023-04-1765
OA
Molecular determinants of KRAS p.G12C inhibitor efficacy in advanced NSCLC
2023-04-040
PRE
Osimertinib in NSCLC With Atypical EGFR-Activating Mutations: A Retrospective Multicenter Study

奥希替尼治疗非典型EGFR激活突变的非小细胞肺癌: 一项回顾性多中心研究

2023-03-0120
OA
AXL and Error-Prone DNA Replication Confer Drug Resistance and Offer Strategies to Treat EGFR-Mutant Lung Cancer
2022-07-2757
OAAI
Deficiency of the splicing factor RBM10 limits EGFR inhibitor response in EGFR-mutant lung cancer
2022-07-0133
OAAI